Health care organization and use of technological devices in people with diabetes in Italy: Result from a survey of the working group on diabetes and technology
Pitocco D, Laurenzi A, Tomaselli L, et al.
NMCD. Published online, 14 July 2022
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Leite AR, Angélico-Gonçalves A, Vasques-Nóvoa F, et al
Diabetes Obes Metab. 2022 Aug;24(8):1676-1680
Leggi
Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: perspective based on the updated evidence
Khunti K, Aroda VR, Bhatt DL, et al.
Diabetes Obes Metab. 2022, Jul 8
Leggi
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Zou X, Huang Q, Luo Y
Diabetologia. 2022 Jul 8. Online ahead of print
Leggi
Obesity and weight management for prevention and treatment of type 2 diabetes
Jiang C, Cifu AS, Sam S
JAMA. Published online, 11 July 2022
Leggi
Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: systematic analysis of cardiorenal outcome trials in type 2 diabetes
Zaccardi F, Kloecker DE, Khunti K, Davies MJ
Diabetes Obes Metab. 2022;24(8):1598-1606.
Leggi
Socioeconomic deprivation is associated with reduced efficacy of an insulin adjustment education program for people with type 1 diabetes
Innes CWD, Henshall DE, Wilson B, et al.
Diabet Med. 2022;e14902.
Leggi
Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes
Deng X, Zhang C, Wang P, et al.
J Clin Endocrinol Metab. 2022;107(7):1888-1896.
Leggi
Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study
Ciardullo S, Rea F, Savaré L, et al.
J Clin Endocrinol Metab. 2022;107(7):e2671-e2679.
Leggi
Loss of the incretin effect in type 2 diabetes: a systematic review and meta-analysis
Grespan E, Guolo A, Muscelli E, et al.
J Clin Endocrinol Metab. 2022;107(7):2092-2100.
Leggi